Fluorouracil/Calcipotriene

Phase 3Small molecule

Fluorouracil/Calcipotriene is one of 2 small molecule programs targeting Multiple Actinic Keratoses. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Actinic KeratosesRecruiting

Multiple Actinic KeratosesPhase 3

Recruiting

Competition

Competitive Landscape

1 competitor in Multiple Actinic Keratoses

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Phase 3

1 2

Fluorouracil/Calcipotriene

MM.D. Anderson Cancer Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Multiple Actinic Keratoses

NCT06851507

Clinical

Trials by Indication[1]

Multiple Actinic Keratoses1 trial

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT06851507·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fluorouracil/Calcipotriene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorouracil/Calcipotriene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorouracil/Calcipotriene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MM.D. Anderson Cancer Center

Fluorouracil/Calcipotriene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Multiple Actinic Keratoses1 trial

References

Drug Info

Quick Facts

Related News